Phase 2 Stomach Cancer Trial, Recruiting NCT06759064 Sponsor: Qilu Hospital of Shandong University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT06759064
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stomach (gastric) adenocarcinoma confirmed by a tissue test (pathology)
  • People whose fluid build-up in the abdomen (ascites) has been confirmed to contain cancer cells through a fluid sample test
  • People whose abdominal fluid build-up has been confirmed by a CT scan and is classified as moderate or large in amount (grade 2 or 3)
  • People aged between 18 and 75 years
  • People who have not received any drugs injected directly into the abdominal cavity, or any immunotherapy treatment, in the past 4 weeks
  • People who are in a reasonably stable general condition, with a functional ability score of 70 or above on the Karnofsky scale, and an expected survival of more than 3 months
  • People whose blood counts are within acceptable ranges (including red blood cells, white blood cells, and platelets meeting specific minimum levels)
  • People whose blood clotting function is normal and who do not have a tendency to bleed (based on a specific clotting test result)
  • People whose liver function test results are within acceptable limits
  • People whose kidney function test results are within acceptable limits

Who may not be able to join:

  • People whose abdominal fluid build-up is caused by something other than cancer (for example, liver disease or infection)
  • People who have medical reasons that make immunotherapy unsafe for them (such as long-term steroid use, or a history of radiation-related lung, liver, or bowel damage)
  • People with serious heart or lung conditions that could affect treatment
  • People with extensive internal scarring in the abdomen, trapped pockets of fluid, a history of bowel obstruction, or cancer that has spread very widely to distant parts of the body in a late-stage setting
  • Women who are pregnant, breastfeeding, or planning to become pregnant
  • People with very low blood protein levels (albumin below 30 g/L)
  • People who are known to have had a serious allergic reaction to the trial drug or similar medicines
  • People with other severe ongoing health conditions that, in the treating doctor's judgement, could affect the study results or make participation unsafe
  • People who have difficulty with thinking or memory, or who the treating doctor believes are unlikely to follow the treatment plan consistently
  • People who are currently participating in another clinical trial, or who have done so within the past 4 weeks
  • People who have been diagnosed with another type of cancer in addition to stomach cancer
  • People who, in the treating doctor's overall judgement, are not considered suitable for the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
12 September 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity (DLT) or maximal tolerance dose (MTD) in the Phase Ib stage; Objective response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov